The STREAMLINE-PVI trial is a prospective, single-center, randomly assigned, open-label clinical trial comparing pulsed field ablation (PFA) with cryoballoon ablation (Cryo) for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). A total of 94 patients undergoing first-time PVI will be randomly assigned 1:1 to either PFA or Cryo within standardized Lean Six Sigma (LSS)-optimized procedural workflows.
Official registry: https://clinicaltrials.gov/study/NCT07910370 · St. Josefs-Hospital Wiesbaden GmbH · enrollment listed as 94
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Pulsed Field Ablation (PFA), or Cryoballoon Ablation (Cryo). The registry lists allocation as randomized. The STREAMLINE-PVI trial is a prospective, single-center, randomly assigned, open-label clinical trial comparing pulsed field ablation (PFA) with cryoballoon ablation (Cryo) for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF).
They plan to enroll about 94 people at Wiesbaden. Taking part typically means a procedure as part of the study plus check-ins.
Structured Treatment and Resource Efficiency Assessment With Lean Six Sigma Integration for Pulmonary Vein Isolation
Interventions: Pulsed Field Ablation (PFA), Cryoballoon Ablation (Cryo)
Primary outcome (registry wording): Total Procedure Duration
Joachim R Ehrlich, Prof. Dr.
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This is a single-center prospective watch-and-measure (no experimental treatment required) cohort study of atrial fibrillation patients treated with radiofrequency ablation.
NCT05266144 · Official ClinicalTrials.gov record · Peking Union Medical College Hospital
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm.
NCT05724121 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)
REACT-AF is a multicenter prospective, randomly assigned, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
NCT05836987 · Official ClinicalTrials.gov record · Johns Hopkins University
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary